U.S. Markets closed

Hansen Medical Announces Initiation of Sell-Side Coverage by Wm Smith & Co.

MOUNTAIN VIEW, CA--(Marketwired - Jun 25, 2013) -  Hansen Medical, Inc. ( NASDAQ : HNSN ), a global leader in intravascular robotics, today announced that Wm Smith & Co. has initiated sell-side coverage of Hansen Medical. The report was authored by Sherry Grisewood, CFA. 

About Analyst Coverage of Hansen Medical
Hansen Medical is followed by several analysts, including Wm Smith & Co. Any opinions, estimates, forecasts or statements regarding Hansen Medical's performance made by Wm Smith & Co. or other analysts are theirs alone and do not represent opinions, estimates, forecasts or statements of Hansen Medical or its management. This press release does not imply Hansen Medical's endorsement of or concurrence with the information, conclusions or recommendations of Wm Smith & Co. or any other analyst.

About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is the global leader in intravascular robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, Magellan Robotic Catheter and related accessories, which are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, have undergone both CE marking and 510(k) clearance and are commercially available in the European Union, and the U.S. In the European Union, the Company's Sensei® X Robotic Catheter System and Artisan Control Catheter are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S. the Company's Sensei X Robotic Catheter System and Artisan Control Catheter were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X System and Artisan Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at www.hansenmedical.com

About Wm Smith & Co.
Wm Smith & Co. is an independent research company providing objective, fundamental equity research on a variety of companies to a select group of institutional clients from both the traditional and alternative investment arena. Founded in 1992, the firm is headquartered in Colorado.